1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Tenapanor (Irritable Bowel Syndrome) - Forecast and Market Analysis to 2023

Tenapanor (Irritable Bowel Syndrome) - Forecast and Market Analysis to 2023

Summary

Irritable Bowel Syndrome (IBS) is a common disorder characterized by abdominal discomfort associated with altered bowel function. Although IBS is not a life-threatening disorder, it has a considerable effect on patients’ quality of life (QOL). In terms of volume, the IBS market is a large, albeit naïve, one, with only a small number of pharmacotherapies indicated for the treatment of the disorder, and it is also characterized by significant unmet needs.

Tenapanor is being developed for the treatment of IBS-C. It was initially developed by Ardelyx, but in October 2012, the company entered into a partnership with AstraZeneca, which gained the exclusive worldwide licensing rights to tenapanor (Ardelyx, press release, October 8, 2012).

Scope

- Overview of IBS, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Tenapanor including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Tenapanor for the top 7 countries from 2013 to 2023.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, and Japan.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return.
- Stay ahead of the competition by understanding the changing competitive landscape for IBS.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.
- Make more informed business decisions from insightful and in-depth analysis of Tenapanor performance.
- Obtain sales forecast for Tenapanor from 2013-2023 in top 7 countries (the US, France, Germany, Italy, Spain, the UK, and Japan).

Table Of Contents

Tenapanor (Irritable Bowel Syndrome) - Forecast and Market Analysis to 2023
1 Table of Contents
2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 9
3 Disease Overview 11
3.1 Etiology and Pathophysiology 11
3.1.1 Etiology 11
3.1.2 Pathophysiology 12
3.2 Classification 12
3.3 Symptoms 13
3.4 Prognosis 14
3.5 Quality of Life 14
4 Disease Management 15
4.1 Diagnosis and Treatment Overview 15
4.1.1 Diagnosis 15
4.1.2 Treatment Guidelines and Leading Prescribed Drugs 17
4.1.3 Clinical Practice 20
5 Competitive Assessment 22
5.1 Overview 22
6 Unmet Need and Opportunity 24
6.1 Overview 24
6.2 More Effective Pharmacotherapies 25
6.2.1 Unmet Need 25
6.2.2 Gap Analysis 26
6.2.3 Opportunity 27
6.3 Therapies for the IBS-D Subtype 27
6.3.1 Unmet Need 27
6.3.2 Gap Analysis 28
6.3.3 Opportunity 28
6.4 Therapies for the IBS-M Subtype 28
6.4.1 Unmet Need 28
6.4.2 Gap Analysis 29
6.4.3 Opportunity 29
6.5 Therapies to Address Abdominal Pain and Bloating Symptoms 29
6.5.1 Unmet Need 29
6.5.2 Gap Analysis 30
6.5.3 Opportunity 30
6.6 Improved Diagnosis Rate for IBS 31
6.6.1 Unmet Need 31
6.6.2 Gap Analysis 31
6.6.3 Opportunity 31
7 Pipeline Assessment 33
7.1 Overview 33
7.2 Promising Drugs in Clinical Development 33
8 Tenapanor (AZD1722, RDX5791) 36
8.1 Overview 36
8.2 Efficacy 37
8.3 Safety 38
8.4 Dosing and Formulation 38
8.5 Potential Clinical and Commercial Positioning 39
8.6 SWOT Analysis 39
8.7 Forecast 40
9 Appendix 41
9.1 Bibliography 41
9.2 Abbreviations 44
9.3 Methodology 46
9.4 Forecasting Methodology 46
9.4.1 Diagnosed IBS Patients 46
9.4.2 General Pricing Assumptions 47
9.4.3 Generic Erosion 48
9.4.4 Pricing of Pipeline Agents 48
9.5 Primary Research - KOLs Interviewed for This Report 49
9.6 Primary Research - Prescriber Survey 51
9.7 About the Authors 52
9.7.1 Analyst 52
9.7.2 Therapy Area Director 52
9.7.3 Global Head of Healthcare 53
9.8 About GlobalData 54
9.9 Disclaimer 54

1.1 List of Tables

Table 1: Common Symptoms of IBS 13
Table 2: Summary of the Various Diagnostic Criteria Used for the Diagnosis of IBS 16
Table 3: Treatment Guidelines for IBS 18
Table 4: Leading Prescribed Drugs for IBS by Predominant Symptoms in the 7MM, 2014† 19
Table 5: Leading Branded Treatments for IBS, 2014 23
Table 6: Unmet Needs and Opportunities in IBS 25
Table 7: Drugs in Late-Stage Clinical Development for IBS, 2014 35
Table 8: Product Profile - Tenapanor 37
Table 9: Tenapanor SWOT Analysis, 2014 39
Table 10: Global IBS Sales Forecasts ($m) for Tenapanor, 2013-2023 40
Table 11: High-Prescribing Physicians (Non-KOLs) Surveyed, by Country 51

1.2 List of Figures

Figure 1: Summary of Pharmacotherapies Used to Treat IBS 21
Figure 2: IBS - Phase IIb-III Pipeline, October 2014 34
Figure 3: Competitive Assessment of Late-Stage Pipeline Agents in IBS, 2013-2023 34
Figure 4: Clinical and Commercial Positioning of Tenapanor 39

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025 Summary Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality ...

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Hepatitis C: Kol Insight

September 2016 $ 8085

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.